Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities:
Net loss	$ (203,889)	$ (273,156)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	52,409	63,689
Depreciation and amortization	3,466	4,052
Net loss from investment in equity securities	23,228	1,117
Gain from sale of priority review voucher, excluding transaction costs	(110,000)
Gain from recognition of receivable from licensing and collaboration agreement	(12,500)
Fair value of shares issued under a license agreements	4,567
Accretion of debt	4,383	2,653
Fair value adjustment of warrants	1,390
Loss on sale of certain assets	6,261
Impairment of long-lived assets	12,653	3,300
LEO call option income		(5,550)
Other noncash adjustments	3,742	3,906
Changes in operating assets and liabilities:
Accounts receivable		(1,040)
Receivable from licensing and collaboration agreements	2,993	(35,363)
Receivable from a related party		(8,962)
Prepaid expenses and other current assets	(3,021)	1,400
Other assets	8,691	(5,723)
Accounts payable	(3,090)	13,025
Accrued compensation and benefits	(9,402)	(8,494)
Accrued research and development liabilities	5,953	2,463
Accrued professional services	(602)	1,499
Operating lease liabilities	(3,348)	(2,776)
Deferred revenue	16,641
Other accrued and other long-term liabilities	8,387	2,599
Net cash used in operating activities	(191,088)	(242,478)
Investing activities:
Purchases of marketable securities	(119,611)	(509,934)
Maturities of marketable securities	293,919	238,934
Purchases of investment in equity securities	(10,930)	(20,000)
Sales of investment in equity securities	9,708
Increase in cash and cash equivalents from consolidation of PellePharm		13,654
Proceeds from sale of priority review voucher	110,000
Proceeds from sale of certain assets	10,000
Payment for an intangible asset	(1,500)
Purchases of property and equipment	(3,261)	(4,248)
Net cash provided by (used in) investing activities	288,325	(281,594)
Financing activities:
Proceeds from issuance of 2029 Notes		747,500
Issuance costs and discounts associated with issuance of 2029 Notes		(16,064)
Issuance costs associated with term loan	(1,120)
Purchase of capped calls		(61,295)
Repurchases of common stock		(55,308)
Transactions with noncontrolling interests		70
Repurchase of Eidos noncontrolling interest, including direct transaction costs		(84,840)
Proceeds from term loan		25,000
Repayment of term loan	(20,486)	(18,108)
Proceeds from BridgeBio common stock issuances under ESPP	966	1,652
Repurchase of shares to satisfy tax withholding	(476)	(3,302)
Proceeds from stock option exercises, net of repurchases	160	11,216
Net cash provided by (used in) financing activities	(20,956)	546,521
Net increase in cash, cash equivalents and restricted cash	76,281	22,449
Cash, cash equivalents and restricted cash at beginning of period	396,365	358,679
Cash, cash equivalents and restricted cash at end of period	472,646	381,128
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	25,435	10,814
Supplemental Disclosures of Noncash Investing and Financing Information:
Payment-in-kind interest added to principal of term loan	5,075
Net noncash portion of repurchase of Eidos noncontrolling interests		38,167
Direct transaction costs in the repurchase of Eidos recorded in "Additional paid-in capital" previously classified in "Prepaid expenses and other current assets"		8,749
Noncash contribution by a noncontrolling interest		21,600
Recognized intangible asset recorded in "Accrued research and development liabilities"		20,000
Leasehold improvements paid by landlord		2,136
Unpaid property and equipment	73	1,323
Transfers from noncontrolling interests (Note 6)	1,456	274
Reconciliation of Cash, Cash Equivalents and Restricted Cash:
Cash and cash equivalents	470,098	378,420
Restricted cash - Included in "Prepaid expenses and other current assets"	140	176
Restricted cash - Included in "Other assets"	2,408	2,532
Total cash, cash equivalents and restricted cash at end of period shown in the condensed consolidated statements of cash flows	$ 472,646	$ 381,128